5 Key Takeaways

• 1

  Tirzepatide is associated with a lower 1-year risk of major adverse cardiovascular events compared to sitagliptin in patients with type 2 diabetes.

• 2

  The study analyzed data from 52,971 patients aged 40 and older who initiated tirzepatide or sitagliptin between May 2022 and May 2025.

• 3

  At 1 year, the weighted risk of major adverse cardiovascular events was approximately 3% for tirzepatide and 4% for sitagliptin.

• 4

  Tirzepatide was linked to fewer infection-related hospital admissions and lower infection-related mortality compared to sitagliptin.

• 5

  The study's limitations include a relatively short follow-up period and potential residual confounding affecting mortality findings.